- Home
- JOF vs TNXP Comparison
JOF vs TNXP Comparison
Compare JOF & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JOF
- TNXP
- Stock Information
- Founded
- JOF 1990
- TNXP 2007
- Country
- JOF Japan
- TNXP United States
- Employees
- JOF N/A
- TNXP N/A
- Industry
- JOF Trusts Except Educational Religious and Charitable
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- JOF Finance
- TNXP Health Care
- Exchange
- JOF Nasdaq
- TNXP Nasdaq
- Market Cap
- JOF 295.0M
- TNXP 335.6M
- IPO Year
- JOF N/A
- TNXP N/A
- Fundamental
- Price
- JOF $10.87
- TNXP $27.11
- Analyst Decision
- JOF
- TNXP Buy
- Analyst Count
- JOF 0
- TNXP 1
- Target Price
- JOF N/A
- TNXP $70.00
- AVG Volume (30 Days)
- JOF 43.9K
- TNXP 1.8M
- Earning Date
- JOF 01-01-0001
- TNXP 11-11-2025
- Dividend Yield
- JOF 3.33%
- TNXP N/A
- EPS Growth
- JOF N/A
- TNXP N/A
- EPS
- JOF N/A
- TNXP N/A
- Revenue
- JOF N/A
- TNXP $9,831,000.00
- Revenue This Year
- JOF N/A
- TNXP $21.19
- Revenue Next Year
- JOF N/A
- TNXP $722.94
- P/E Ratio
- JOF N/A
- TNXP N/A
- Revenue Growth
- JOF N/A
- TNXP N/A
- 52 Week Low
- JOF $6.64
- TNXP $6.76
- 52 Week High
- JOF $8.04
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- JOF 64.70
- TNXP 38.45
- Support Level
- JOF $10.78
- TNXP $24.20
- Resistance Level
- JOF $10.98
- TNXP $31.55
- Average True Range (ATR)
- JOF 0.11
- TNXP 2.30
- MACD
- JOF -0.01
- TNXP 0.02
- Stochastic Oscillator
- JOF 78.26
- TNXP 26.66
About JOF Japan Smaller Capitalization Fund Inc
Japan Smaller Capitalization Fund Inc is a closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.